Skip to main content

Table 2 Analyses of HMA combinations with Doxo on BCP-ALL cells

From: Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

 

Drug combination effect

AZA + Doxo

AZA + Doxo (24 h)

Doxo + AZA (24 h)

DEC + Doxo

DEC + Doxo (24 h)

Doxo + DEC (24 h)

SEM

Metabolism

− 0.071

− 0.230

0.006

− 0.046

− 0.117

− 0.021

Proliferation

− 0.002

− 0.192

0.015

− 0.014

− 0.094

− 0.042

RS4;11

Metabolism

− 0.009

− 0.118

0.086

− 0.007

− 0.071

0.044

Proliferation

− 0.022

− 0.227

0.016

− 0.028

− 0.301

0.011

  1. Drug combination effect: difference between the observed and the expected inhibition (E) of combined treatment. E is calculated as follows: E = (A + B) − (A*B); A is inhibition effect of drug A; B inhibition effect of drug B values > 0: synergistic, values < 0: antagonistic
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us